» Articles » PMID: 23514379

Serotonin-kynurenine Hypothesis of Depression: Historical Overview and Recent Developments

Overview
Specialty Pharmacology
Date 2013 Mar 22
PMID 23514379
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

This mini-review focuses on the studies of late Prof. IP Lapin (1903 - 2012) and his research team on the role of methoxyindole and kynurenine (KYN) pathways of tryptophan (TRP) metabolism in the pathogenesis of depression and action mechanisms of antidepressant effect. In the late 60s of the last century Prof. IP Lapin suggested that "intensification of central serotoninergic processes is a determinant of the thymoleptic (mood elevating) component" while "activation of noradrenergic processes is responsible for psychoenergetic and motor-stimulating component of the clinical antidepressant effect". The cause of serotonin deficiency in depression was attributed to the shunt of TRP "metabolism away from serotonin production towards KYN production" due to cortisol-induced activation of liver enzyme, tryptophan 2,3- dioxygenase, the rate-limiting enzyme of TRP - KYN pathway. Prof. Lapin suggested and discovered that KYN and its metabolites affect brain functions, and proposed the role of neurokynurenines in pathogenesis of depression and action mechanisms of antidepressant effect (kynurenine hypothesis). Further research suggested the antidepressant and cognition- enhancing effects of post-serotonin metabolite, N-acetylserotonin (NAS), an agonist to tyrosine kinase B (TrkB) receptor; and link between depression and chronic inflammation-associated disorders (e.g., insulin resistance, hepatitis C virus) via inflammation-induced activation of indoleamine 2,3- dioxygenase, brain located rate-limiting enzyme of TRY - KYN metabolism. NAS and kynurenines might be the targets for prevention and treatment of depression and associated conditions.

Citing Articles

Anthranilic Acid-G-Protein Coupled Receptor109A-Cytosolic Phospholipase A2-Myelin-Cognition Cascade: A New Target for the Treatment/Prevention of Cognitive Impairment in Schizophrenia, Dementia, and Aging.

Oxenkrug G Int J Mol Sci. 2025; 25(24.

PMID: 39769034 PMC: 11675959. DOI: 10.3390/ijms252413269.


Association between small intestine bacterial overgrowth and psychiatric disorders.

Bogielski B, Michalczyk K, Glodek P, Tempka B, Gebski W, Stygar D Front Endocrinol (Lausanne). 2024; 15:1438066.

PMID: 39497810 PMC: 11532184. DOI: 10.3389/fendo.2024.1438066.


Biomarkers of microbial translocation and generalized inflammation are associated with frailty among people with HIV.

Ruderman S, Hunt P, Beck-Engeser G, Ambayec G, Willig A, Saag M AIDS. 2024; 39(2):153-161.

PMID: 39453872 PMC: 11717601. DOI: 10.1097/QAD.0000000000004047.


Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities.

Pocivavsek A, Schwarcz R, Erhardt S Pharmacol Rev. 2024; 76(6):978-1008.

PMID: 39304346 PMC: 11549936. DOI: 10.1124/pharmrev.124.000239.


Heme-based dioxygenases: Structure, function and dynamics.

Geeraerts Z, Ishigami I, Gao Y, Yeh S J Inorg Biochem. 2024; 261:112707.

PMID: 39217822 PMC: 11590650. DOI: 10.1016/j.jinorgbio.2024.112707.


References
1.
Oxenkrug G, McIntyre I, McCauley R, Yuwiler A . Effect of selective monoamine oxidase inhibitors on rat pineal melatonin synthesis in vitro. J Pineal Res. 1988; 5(1):99-109. DOI: 10.1111/j.1600-079x.1988.tb00772.x. View

2.
Campesan S, Green E, Breda C, Sathyasaikumar K, Muchowski P, Schwarcz R . The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr Biol. 2011; 21(11):961-6. PMC: 3929356. DOI: 10.1016/j.cub.2011.04.028. View

3.
Milasius A, Grinevicius K, Lapin I . Effect of quinolinic acid on wakefulness and sleep in the rabbit. J Neural Transm Gen Sect. 1990; 82(1):67-73. DOI: 10.1007/BF01244835. View

4.
Bachurin S, Shevtsova E, Kireeva E, Oxenkrug G, Sablin S . Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci. 2003; 993:334-44; discussion 345-9. DOI: 10.1111/j.1749-6632.2003.tb07541.x. View

5.
Coppen A . Depressed states and indolealkylamines. Adv Pharmacol (1962). 1968; 6(Pt B):283-91. DOI: 10.1016/s1054-3589(08)60328-2. View